- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04541433
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- Tumor Activity of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Primary objective:
To investigate the safety and tolerability of AZD9833 in Japanese women with ER+ HER2- advanced breast cancer
Secondary objective:
To assess the anti-tumor activity and efficacy of AZD9833
Exploratory objectives:
To investigate AZD9833 activity in tumor cells
Overall design:
This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with endocrineresistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent. Eligible patients will receive AZD9833. In cohort 1 (for tolerability evaluation), a minimum of 3 to maximum 6 evaluable patients will be enrolled.
For cohort 2, if paired biopsy after administration of the study drug becomes inoperable during administration of the study drug, additional subjects can be added to obtain an evaluable biopsy sample.
In cohort 2 (for exploratory research), eligible patients will receive AZD9833 once daily and at least 6 to maximum 12 patients will be enrolled. In cohort 2, paired biopsy sample will be collected from at least 6 and maximum 12 patients. If paired biopsy after administration of the study drug becomes inoperable during administration of the study drug, additional subjects can be added to obtain an evaluable biopsy sample.
Number of Subjects:
Maximum 18 evaluable subjects will be enrolled in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chuo-ku, Japan, 104-0045
- Research Site
-
Kashiwa, Japan, 277-8577
- Research Site
-
Koto-ku, Japan, 135-8550
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Major Inclusion Criteria:
- Signed written informed consent.
- >= 20 years.
Any menopausal status:
Pre and Post menopausal defined according to standard criteria in the protocol.
- Histological or cytological confirmation of adenocarcinoma of the breast.
- Documented positive estrogen receptor status of primary or metastatic tumor tissue, according to the local laboratory parameters. HER-2 negative.
- Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP.
Prior chemotherapy, endocrine therapy and other therapy in the advanced setting is restricted as follows:
- No more than 2 lines of chemotherapy for advanced disease.
- Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
- There is no limit on the number of lines of prior endocrine therapies.
- Prior treatment with CDK4/6 inhibitors is permitted.
- At least one lesion (measurable and/or non-measurable, as per RECIST 1.1) that can be accurately assessed at baseline and is suitable for repeated assessment by computed tomography (CT), magnetic resonance imaging (MRI), or plain X-ray; or clinical examination.
- Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1
Major Exclusion Criteria:
Intervention with any of the following:
- Any cytotoxic chemotherapy, investigational agents, or other anti-cancer drugs for the treatment of advanced breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
- Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 (CYP) 3A4/5 sensitive CYP2B6 substrates and drugs which are substrates of CYP2C9 and/or CYP2C19.
- Drugs that are known to prolong QT and have a known risk of Torsades de Pointes.
- Radiotherapy with a limited field of radiation for palliation within one week of the first dose of IMP, radiotherapy to more than 30% of the bone marrow or a wide field of radiation within 4 weeks of the first dose of IMP.
- Major surgical procedure or significant traumatic injury.
- Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting IMP.
- Presence of life-threatening metastatic visceral disease.
- Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses.
- Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.
- History of another primary malignancy.
- Male subjects are excluded from this study.
- History of hypersensitivity to active or inactive excipients of AZD9833.
- The following cardiovascular criteria: QTcF >470 ms, resting heart rate <45 bpm, clinically significant abnormalities of resting electrocardiogram, uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, left ventricular ejection fraction <50%.
- Inadequate bone marrow reserve or organ function
- Involvement in the planning and conduct of the study.
- Judgment by the investigator that the patient should not participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD9833 monotherapy
Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
|
AZD9833 taken orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of subjects with dose-limiting toxicity, as defined in the protocol.
Time Frame: From the first dose of study treatment up to and including Cycle1 Day28.
|
Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.
|
From the first dose of study treatment up to and including Cycle1 Day28.
|
The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.
Time Frame: Minimum observation period 28 days on treatment or 28 days with at least 75% of the required dose and will continue until the subject is off the study (approximately 1 year).
|
Safety data will be assessed as the number of subjects with treatment-related adverse events.
|
Minimum observation period 28 days on treatment or 28 days with at least 75% of the required dose and will continue until the subject is off the study (approximately 1 year).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit rate at 24 weeks
Time Frame: Up to 24 weeks
|
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
|
Up to 24 weeks
|
Objective Response Rate
Time Frame: At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).
|
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
|
At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).
|
Duration of Response
Time Frame: At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).
|
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
|
At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).
|
Percentage Change in Tumour Size
Time Frame: At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).
|
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
|
At Cycle3 Day1, Cycle5 Day1, Cycle7 Day1 (each cycle is 28 days) and every 12 weeks until the end of the study (approximately 1 year).
|
Progression Free Survival
Time Frame: Up to objective disease progression or death (approximately 1 year).
|
Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
|
Up to objective disease progression or death (approximately 1 year).
|
Maximum Observed Plasma Concentration (Cmax) of AZD9833
Time Frame: At predefined intervals throughout the AZD9833 treatment period (approximately 12 weeks )
|
Blood samples will be collected to assess plasma concentrations of AZD9833 at a series of timepoints to derive Cmax
|
At predefined intervals throughout the AZD9833 treatment period (approximately 12 weeks )
|
Time to observed Cmax (Tmax) for AZD9833
Time Frame: At predefined intervals throughout the AZD9833 treatment period (approximately 12 weeks )
|
Blood samples will be collected to assess plasma concentrations of AZD9833 at a series of timepoints to derive Tmax
|
At predefined intervals throughout the AZD9833 treatment period (approximately 12 weeks )
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D8530C00006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ER+ HER2- Advanced Breast Cancer
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerUnited States, Spain, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Terminated
-
AstraZenecaCompletedER+ HER2- Advanced Breast CancerUnited States, United Kingdom, Korea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedER+ / HER2- Advanced Breast CancerChina
-
Stemline Therapeutics, Inc.CompletedAdvanced ER+, HER2-Negative Breast CancerUnited States
-
Shenzhen Yangli Pharmaceutical Technology Co., LtdRecruitingMetastatic Breast Cancer | ER+, HER2- Advanced Breast CancerChina
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerKorea, Republic of, United States, Australia, Hong Kong, Taiwan, Malaysia, Thailand, Argentina
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Clinical Trials on AZD9833
-
AstraZenecaQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
AstraZenecaCompletedHepatic ImpairmentUnited States, Bulgaria, Slovakia
-
AstraZenecaCompletedHER2-negative Breast CancerMexico, United Kingdom, Georgia
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerUnited States, Spain, United Kingdom
-
AstraZenecaQuotient SciencesCompletedER-positive, HER2-negative Breast CancerUnited Kingdom
-
AstraZenecaRecruitingER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)Korea, Republic of, United Kingdom, Australia, United States, Spain
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more